The FDA's CRL release (openFDA transparency/crl, last updated 2026-11-18; snapshot read 2026-11-21) holds 2 Complete Response Letters to this company, dated 2015 to 2019, on 2 applications. The FDA releases letters selectively, so this may not be every letter the company received. Printed in the release as: Mylan Pharmaceuticals Inc. (1); Mylan Pharmaceuticals, Inc. (1).
Grouped on the company name as openFDA prints it, with capitalization, accents, punctuation and corporate-form words (Inc., LLC, Ltd., Limited, Corp., SA, USA and the like) ignored; each row shows the name as printed. A misspelled name forms its own group, and a letter printed with a heading or a bare corporate-form word where the name should be is on no company page, so a count here can be lower than the letters the release holds for a company. Facts only: no view on any outcome.
| Letter date | Application | Name as printed | openFDA status | Orange Book approval after the letter | Sections the letter names |
|---|---|---|---|---|---|
| August 6, 2019 | NDA 204311 | Mylan Pharmaceuticals Inc. | Approved | Abacavir Sulfate And Lamivudin, December 22, 2023 | none read |
| February 27, 2015 | NDA 206610 | Mylan Pharmaceuticals, Inc. | Approved | Acetaminophen, January 15, 2021 | none read |
How each column is made: the letter date and the PDF are the FDA's release; "openFDA status" is openFDA's approval_status field as released; "Orange Book approval" is the earliest approval date the FDA's Orange Book products file (FDA files dated 2026-11-13) lists for the NDA, shown when it falls after the letter date and the letter is not on a supplement; BLAs are not in the Orange Book, so no date is shown for them; "sections" are the letter's own deficiency headings read from its PDF text layer, for letters dated 2024 or later whose PDF holds no other letter from the release ("none read" otherwise, or where no heading could be read).
Every company in the release · facts from all released CRLs · every released letter